Benchmark downgrades RTI Biologics (Nasdaq: RTIX) from Buy to Hold, price target reduced from $5 to $2.70.

The firm ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE